You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
TYMLOS ® new patient adds in April: modest growth vs. previous 4-month trailing averages ~67% of new patients in April were initiated by a fracture focused bone health account Meaningful FDA guidance on generic peptide requirements published on May 19, 2021 Anticipate abaloparatide depot
Total net revenue: $56 million vs. $48 million in Q1, 2020, +17% year-over-year TYMLOS ® U.S. product net revenue: $45 million vs. $48 million in Q1, 2020, -6% year-over-year Significant operating leverage improvement: Q1, 2021 adjusted EBITDA: ($5) million vs.
Growth of 14% for new U.S. TYMLOS® patients in Q1, 2021 vs. Q4, 2020 Q1, 2021 TYMLOS net revenue impacted by seasonality and distribution channel destocking April, 2021 month-to-date new patient adds indicate significant patient growth Three pivotal studies: all remain on track for 2H, 2021
BOSTON , April 20, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021 . The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a
Regulatory success achieved in Japan by partner Teijin Pharma Limited Ostabaro® approved for treatment of male & female OP patients at high risk of fracture Japan is currently the largest anabolic market in the world $10 million milestone to be generated from Japan approval EU: intend to re-file
Repurchases $112.2 million of principal amount of the 3.00% convertible notes due September 1, 2024 (“2024 Notes”), representing approximately 37% of the outstanding 2024 Notes Estimated excess cash proceeds of approximately $14.2 million will be added to the balance sheet Eliminates approximately
Full year 2020 TYMLOS® U.S. net sales of $208 million was year-over-year growth of 20% Q4 2020 TYMLOS U.S. net sales: $60 million was 8% growth vs. Q4 2019 and 19% growth vs. Q3 2020 New patient starts: increased by 26% in Q4 2020 vs. Q3 2020 ATOM, wearABLe and EMERALD studies: on schedule for 2H
BOSTON , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10 th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021 . A live webcast of the presentation will be available
BOSTON , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m.
17% growth in January 2021 for new TYMLOS® patients vs. previous 4 month trailing average Histomorphometry study published: Journal of Bone & Mineral Research in January 2021 Cardiovascular safety study published: Journal of Clinical Endocrinology & Metabolism in November 2020 Japan : with our